Vitamin K2-7 May Slow Progression of Coronary Artery Calcification

Why It Matters

If MK‑7 can reliably slow CAC, it provides a non‑pharmaceutical option to lower heart‑disease risk, potentially reshaping supplement strategies and influencing future cardiovascular guidelines.

Key Takeaways

• MK‑7 cut CAC progression 29% over two years
• Study involved 180 symptomatic CAD patients, 78% on statins
• Effect modest; fast‑progressor rates unchanged
• Mechanism linked to vitamin K‑dependent MGP activation
• Further trials needed to prove event‑level benefits

Pulse Analysis

Coronary artery calcification remains a silent driver of heart attacks, yet no therapy can dissolve existing calcium deposits. Clinicians rely on statins, lifestyle changes, and risk‑factor control to blunt the disease’s advance, while the supplement sector searches for adjunctive agents that can improve arterial health without prescription‑only interventions. In this landscape, vitamin K2‑7, a form of menaquinone, has attracted attention for its role in activating matrix Gla protein, a natural inhibitor of vascular calcification.

The VitaK‑CAC trial, published in JAMA Cardiology, enrolled 180 adults with symptomatic coronary artery disease and baseline CAC scores of 50‑400. Over two years, participants received either 360 µg of MK‑7 daily or a placebo, while the majority continued statin therapy. The MK‑7 group’s CAC score rose from 135 to 184, compared with an increase from 145 to 214 in the placebo arm—a 29% slower progression that reached statistical significance. Researchers attribute the effect to enhanced carboxylation of matrix Gla protein, which keeps calcium out of arterial walls. However, the overall impact was modest, and the proportion of rapid progressors did not differ, underscoring the need for caution before extrapolating to clinical outcomes.

For the supplement industry, the findings represent a potential breakthrough, positioning MK‑7 as a scientifically backed ingredient that could be marketed for cardiovascular health. Yet investors and clinicians will watch for the next phase: a large‑scale outcome trial assessing non‑fatal heart events. Should such a study confirm event‑level benefits, MK‑7 could shift from a niche nutraceutical to a mainstream preventive strategy, prompting updates to guidelines and opening new revenue streams for manufacturers. Until then, the current evidence supports MK‑7 as a modest adjunct, not a substitute for established therapies.